Graeme-David Wald Email & Phone Number

Melbourne, Victoria, Australia

Developing bi-specific antibodies that can target peptide MHC on solid tumors.

Melbourne, Victoria, Australia

Melbourne, Victoria, Australia

Drawbridge is developing a novel general anaesthetic formulation with the potential to become a major player in the market as clinical trials have shown it to be safer than current general anaesthetics. It is also easier to manufacture. I led the corporate restructuring of the company and its recapitalisation. Put in place CMC and clinical strategies, and led negotiations with various service providers. Increased the company's market opportunity from US$1.6B p.a. to over US$3B p.a. Obtained in Principle Approval from the ASX to IPO the company.

Melbourne, Victoria, Australia

Provided advice to stock-broking companies and life-science companies about listing and secondary raises. Advised companies abut clinical trial structures, work required to bring products to market eg CMC and clinical requirements.

Melbourne, Victoria, Australia

Led investment by OneVentures into newly formed Prota Therapeutics, that licensed in technology from Murdoch Children's Hospital. I led the licensing negotiations and due-diligence for One Ventures that was the seed investor. As Chairman and Acting CEO when required, I built the clinical development and regulatory team to develop a novel immunotherapeutic drug treatment for food allergies.

Melbourne, Victoria, Australia

Fund manager specialising in life science companies. Played a major role in the developing the company's successful application to be a beneficiary of the Federal Governments Biomedical Translation Fund. Became a Principal in Healthcare Fund 3, where I sourced most of the Fund's investments. Led due diligence on investments, wrote investment reports, negotiated investment rounds and licensing agreements. Established the company's international Scientific Advisory Board. Led a team of portfolio managers and analysts.

Melbourne, Australia

Investment Director at Bioscience Managers, an international fund manager specialising in the Life Science arena.

Melbourne, Australia

A consulting company specialising investing in and advising life science companies on strategies, products, valuations, indications and regulatory pathways. Companies consulted to include those in the public and private sectors, with interests in respiratory diseases, analgesia and novel delivery systems.

Melbourne

Non-executive director of Nexvet, and chairman of the Risk and Audit Committee. Nexvet is developing a range of monoclonal antibodies (MAb's) for the veterinary market using proprietary technology (PETisation). This technology ensures the MAb is relevant for each respective animal species (dogs, cats and horses).

Running life since research, managing junior analysts and marketing of research reports.

Research analyst

Certificate, Executive Course In Negotiations

Mba

Phd, Chemistry

The study of the electrochemistry in molten NaCl-Ferrous chloride. This investigated the fundamental electrochemistry of the zebra high.

Education record

Worked as a research assistant ion the Department of Chemistry, reporting to Prof. Gleb Mamantov in the field of molten salt.

Student Fellowship, Photoelectrochemistry

B.Sc Honours, Applied Chemistry

B.Sc, Chemistry And Applied Chemistry